Trials / Recruiting
RecruitingNCT06006819
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 155 (estimated)
- Sponsor
- Cheng-Hsin General Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
Conditions
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2025-12-23
- Completion
- 2025-12-23
- First posted
- 2023-08-23
- Last updated
- 2024-08-23
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06006819. Inclusion in this directory is not an endorsement.